Overview

Pelacarsen Roll-over Extension Program

Status:
RECRUITING

Trial end date:
2028-01-03

Target enrollment:

Participant gender:

Summary

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).

Phase:

PHASE3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

pelacarsen